Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Cancer Institute (WIA) · +46 more institutions
Abstract
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the…
Citation impact
- FWCI
- 134.09
- Percentile
- 100%
- References
- 151
Authors
38- EMEdward M. SchaefferCorresponding
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- SSSandy Srinivas
Cancer Institute (WIA), Stanford Cancer Institute
- NANabil Adra
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University
- YAYi An
Yale Cancer Center, Smilow Cancer Hospital
- DADaniel A. Barocas
Breast Cancer Research Foundation, Vanderbilt-Ingram Cancer Center
Topics & keywords
- Medicine
- Prostate cancer
- Androgen deprivation therapy
- Oncology
- Internal medicine
- Disease
- Cancer
- Management of prostate cancer